Replies to post #85690 on Biotech Values

[DewDiligence]

A blogger says MRK’s Boceprevir has been “back-burnered,” which hardly seems credible, IMO:

http://anewmerckreviewed.wordpress.com/2010/03/11/salmon-rises-legacy-schering-ploughs-boceprevir-back-burnered-by-new-merck/

It does not help the blogger’s credibility that he does not even know how to spell Boceprevir:

For Merck to have placed boceprivir on hold and instead move forward a compound in the same class that is much further behind suggests that they don’t think much of boceprivir.

:- )